OTCMKTS:ZLDPF Zealand Pharma A/S (ZLDPF) Stock Price, News & Analysis $119.76 +4.76 (+4.14%) (As of 11/1/2024 08:58 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort Interest About Zealand Pharma A/S Stock (OTCMKTS:ZLDPF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zealand Pharma A/S alerts:Sign Up Key Stats Today's Range$119.76▼$120.0050-Day Range$112.00▼$136.7652-Week Range$40.40▼$141.74Volume400 shsAverage Volume1,969 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company OverviewZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.Read More… CRUSHED: How Biden's Replacement Will Devastate Your 401(k)! (Ad)Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << Receive ZLDPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address ZLDPF Stock News HeadlinesZealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial resultsNovember 1 at 12:30 PM | globenewswire.comNovo and Lilly contender Zealand Pharma heralds its obesity drug alternative: It's our 'crown jewel'October 11, 2024 | msn.comCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.November 4, 2024 | Golden Crest (Ad)Wegovy and Zepbound rival targeting 'next generation' of obesity drugs, Zealand Pharma CEO saysOctober 11, 2024 | cnbc.comZealand, Boehringer win FDA breakthrough status to treat fatty liverOctober 8, 2024 | reuters.comZealand Pharma Gets FDA Complete Response Letter for Hypoglycemia New Drug ApplicationOctober 8, 2024 | marketwatch.comUS FDA declines to approve Zealand's drug for low blood sugar in infantsOctober 8, 2024 | msn.comNew Zealand's Fonterra upgrades dividend payout policySeptember 30, 2024 | reuters.comSee More Headlines ZLDPF Stock Analysis - Frequently Asked Questions How have ZLDPF shares performed this year? Zealand Pharma A/S's stock was trading at $55.65 at the beginning of the year. Since then, ZLDPF shares have increased by 115.2% and is now trading at $119.76. View the best growth stocks for 2024 here. How were Zealand Pharma A/S's earnings last quarter? Zealand Pharma A/S (OTCMKTS:ZLDPF) announced its quarterly earnings data on Thursday, August, 15th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by $0.06. The company earned $4.93 million during the quarter, compared to analyst estimates of $0.50 million. Zealand Pharma A/S had a negative trailing twelve-month return on equity of 18.17% and a negative net margin of 191.92%. How do I buy shares of Zealand Pharma A/S? Shares of ZLDPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/15/2024Today11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:ZLDPF Previous SymbolNASDAQ:ZLDPF CUSIPN/A CIKN/A Webwww.zealandpharma.com Phone45-8877-3600Fax45-8877-3898Employees340Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,180,000.00 Net Margins-191.92% Pretax Margin-193.54% Return on Equity-18.17% Return on Assets-15.88% Debt Debt-to-Equity Ratio0.03 Current Ratio35.57 Quick Ratio35.57 Sales & Book Value Annual Sales$49.75 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.49 per share Price / Book26.67Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.96 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (OTCMKTS:ZLDPF) was last updated on 11/4/2024 by MarketBeat.com Staff From Our PartnersCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a ...Golden Crest | Sponsored[Charles Payne Live Event] Click to Confirm Your RSVPThe Blueprint to Protect Your Portfolio Charles Payne reveals a strategy few investors know about Unstoppable Prosperity | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zealand Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Zealand Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.